Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000796229 | SCV000935734 | likely benign | Autosomal dominant nocturnal frontal lobe epilepsy | 2023-02-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001766640 | SCV001998004 | uncertain significance | not provided | 2019-10-15 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge; This amino acid substitution is not predicted to occur within the transmembrane region of the protein, where the vast majority of pathogenic missense variants have been identified in association with epilepsy (Steinlein et al., 2010). |
Prevention |
RCV003965590 | SCV004782072 | uncertain significance | CHRNA2-related disorder | 2024-02-02 | no assertion criteria provided | clinical testing | The CHRNA2 c.215G>A variant is predicted to result in the amino acid substitution p.Arg72His. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0080% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |